ReP USP - Resultado da busca

Artigo de periodico
Immune evasion of SARS-CoV-2 omicron subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a cohort of older adults after ChAdOx1-S vaccination and BA.4/5 bivalent Booster (2024)
Machado, Rafael Rahal Guaragna ; Candido, Erika Donizette de Oliveira ; Aguiar, Andressa Simões ; Chalup, Vanessa Nascimento ; Sanches, Patricia Romão ; Dorlass, Erick Gustavo ; Amgarten, Deyvid Emanuel ; Pinho, João Renato Rebello ; Oliveira, Danielle Bruna Leal de
Fonte: Vaccines. Unidades: FM, ICB, BIOINFORMÁTICA
Assuntos: MICROBIOLOGIA, COVID-19, INFECÇÕES POR CORONAVIRUS, VACINAS VIRAIS, VARIAÇÃO GENÉTICA, MUTAÇÃO GENÉTICA, ANTICORPOS, ESTUDOS DE COORTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Rafael Rahal Guaragna et al. Immune evasion of SARS-CoV-2 omicron subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a cohort of older adults after ChAdOx1-S vaccination and BA.4/5 bivalent Booster. Vaccines, v. 12, n. 2, 2024Tradução . . Disponível em: https://doi.org/10.3390/vaccines12020144. Acesso em: 20 jul. 2024.
APA
Machado, R. R. G., Candido, E. D. de O., Aguiar, A. S., Chalup, V. N., Sanches, P. R., Dorlass, E. G., et al. (2024). Immune evasion of SARS-CoV-2 omicron subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a cohort of older adults after ChAdOx1-S vaccination and BA.4/5 bivalent Booster. Vaccines, 12( 2). doi:10.3390/vaccines12020144
NLM
Machado RRG, Candido ED de O, Aguiar AS, Chalup VN, Sanches PR, Dorlass EG, Amgarten DE, Pinho JRR, Oliveira DBL de. Immune evasion of SARS-CoV-2 omicron subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a cohort of older adults after ChAdOx1-S vaccination and BA.4/5 bivalent Booster [Internet]. Vaccines. 2024 ; 12( 2):[citado 2024 jul. 20 ] Available from: https://doi.org/10.3390/vaccines12020144
Vancouver
Machado RRG, Candido ED de O, Aguiar AS, Chalup VN, Sanches PR, Dorlass EG, Amgarten DE, Pinho JRR, Oliveira DBL de. Immune evasion of SARS-CoV-2 omicron subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a cohort of older adults after ChAdOx1-S vaccination and BA.4/5 bivalent Booster [Internet]. Vaccines. 2024 ; 12( 2):[citado 2024 jul. 20 ] Available from: https://doi.org/10.3390/vaccines12020144
Artigo de periodico
Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future (2024)
Souza, Milena Silva ; Farias, Jéssica Pires ; Santos, Robert Andreata ; Silva, Marianne Pereira; Brito, Ruth Dálety da Silva; Silva, Marcia Duarte Barbosa da; Peter, Cristina Mendes; Cirilo, Marcus Vinicius de França ; Luiz, Wilson Barros ; Birbrair, Alexander ; Vidal, Paloma Oliveira ; Amarante, Maria Fernanda Castro ; Candido, Erika Donizette de Oliveira ; Munhoz, Aldilene Silva ; Malta, Fernanda de Mello ; Dorlass, Erick Gustavo ; Machado, Rafael Rahal Guaragna ; Pinho, Joao Renato Rebello ; Oliveira, Danielle Bruna Leal de ; Maricato, Juliana Terzi ; Braconi, Carla Torres ; Janini, Luiz Mário Ramos ; Amorim, Jaime Henrique ; Ferreira, Luis Carlos de Souza ; Durigon, Edison Luiz
Fonte: Journal of Medical Virology. Unidade: ICB
Assuntos: MICROBIOLOGIA, EPITOPOS, COVID-19, VACINAS VIRAIS, GLICOPROTEÍNAS DA MEMBRANA, ANTICORPOS, VARIAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Milena Silva et al. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future. Journal of Medical Virology, v. 96, n. 2, p. 9 , 2024Tradução . . Disponível em: https://doi.org/10.1002/jmv.29416. Acesso em: 20 jul. 2024.
APA
Souza, M. S., Farias, J. P., Santos, R. A., Silva, M. P., Brito, R. D. da S., Silva, M. D. B. da, et al. (2024). Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future. Journal of Medical Virology, 96( 2), 9 . doi:10.1002/jmv.29416
NLM
Souza MS, Farias JP, Santos RA, Silva MP, Brito RD da S, Silva MDB da, Peter CM, Cirilo MV de F, Luiz WB, Birbrair A, Vidal PO, Amarante MFC, Candido ED de O, Munhoz AS, Malta F de M, Dorlass EG, Machado RRG, Pinho JRR, Oliveira DBL de, Maricato JT, Braconi CT, Janini LMR, Amorim JH, Ferreira LC de S, Durigon EL. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future [Internet]. Journal of Medical Virology. 2024 ; 96( 2): 9 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1002/jmv.29416
Vancouver
Souza MS, Farias JP, Santos RA, Silva MP, Brito RD da S, Silva MDB da, Peter CM, Cirilo MV de F, Luiz WB, Birbrair A, Vidal PO, Amarante MFC, Candido ED de O, Munhoz AS, Malta F de M, Dorlass EG, Machado RRG, Pinho JRR, Oliveira DBL de, Maricato JT, Braconi CT, Janini LMR, Amorim JH, Ferreira LC de S, Durigon EL. Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: insights to the future [Internet]. Journal of Medical Virology. 2024 ; 96( 2): 9 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1002/jmv.29416
Artigo de periodico
Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape (2023)
Oliveira, Jamille Ramos ; Ruiz, Cesar Manuel Remuzgo ; Machado, Rafael Rahal Guaragna ; Urbanski, Alysson Henrique ; Magawa, Jhosiene Yukari; Daher, Isabela Pazotti; Urbanski, Alysson Henrique ; Schmitz, Gabriela Justamante Händel ; Arcuri, Helen Andrade; Ferreira, Marcelo Alves ; Sasahara, Greyce Luri ; Medeiros, Giuliana Xavier de ; Silva Júnior, Roberto Carlos Vieira da ; Rosa, Daniela Santoro ; Nakaya, Helder Takashi Imoto ; Gadermaier, Gabriele; Coelho, Verônica ; Santos, Keity Souza ; Durigon, Edison Luiz ; Boscardin, Silvia Beatriz ; Schechtman, Deborah ; Cunha Neto, Edecio; Kalil Filho, Jorge Elias ; Coelho, Veronica Porto Carreiro de Vasconcellos
Fonte: Frontiers in Immunology. Unidades: ICB, IQ, FM, FCF
Assuntos: MICROBIOLOGIA, PARASITOLOGIA, ANTICORPOS, COVID-19, VACINAS VIRAIS, EPITOPOS, IMUNOGLOBULINAS, VARIAÇÃO GENÉTICA, MUTAÇÃO GENÉTICA, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Jamille Ramos et al. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Frontiers in Immunology, v. 13, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.1010105. Acesso em: 20 jul. 2024.
APA
Oliveira, J. R., Ruiz, C. M. R., Machado, R. R. G., Urbanski, A. H., Magawa, J. Y., Daher, I. P., et al. (2023). Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Frontiers in Immunology, 13, 1-15. doi:10.3389/fimmu.2022.1010105
NLM
Oliveira JR, Ruiz CMR, Machado RRG, Urbanski AH, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Arcuri HA, Ferreira MA, Sasahara GL, Medeiros GX de, Silva Júnior RCV da, Rosa DS, Nakaya HTI, Gadermaier G, Coelho V, Santos KS, Durigon EL, Boscardin SB, Schechtman D, Cunha Neto E, Kalil Filho JE, Coelho VPC de V. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape [Internet]. Frontiers in Immunology. 2023 ; 13 1-15.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fimmu.2022.1010105
Vancouver
Oliveira JR, Ruiz CMR, Machado RRG, Urbanski AH, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Arcuri HA, Ferreira MA, Sasahara GL, Medeiros GX de, Silva Júnior RCV da, Rosa DS, Nakaya HTI, Gadermaier G, Coelho V, Santos KS, Durigon EL, Boscardin SB, Schechtman D, Cunha Neto E, Kalil Filho JE, Coelho VPC de V. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape [Internet]. Frontiers in Immunology. 2023 ; 13 1-15.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fimmu.2022.1010105
Artigo de periodico
Identification of Zika Virus NS1-Derived Peptides with potential applications in serological tests (2023)
Prudencio, Carlos Roberto ; Costa, Vivaldo Gomes da ; Rocha, Leticia Barboza ; Costa, Hernan Hermes Monteiro ; Orts, Diego José Belato y ; Santos, Felipe Rocha da Silva ; Paula Rahal ; Lino, Nikolas Alexander Borsato ; Conceição, Pâmela Jóyce Previdelli da ; Bittar, Cintia ; Machado, Rafael Rahal Guaragna ; Durigon, Edison Luiz ; Araujo Jr., João Pessoa ; Polatto, Juliana Moutinho ; Miriam Aparecida da Silva ; Oliveira, Joyce Araujo de ; Mitsunari, Thaís ; Pereira, Lennon Ramos ; Andreata-Santos, Robert ; Ferreira, Luís Carlos de Souza ; Luz, Daniela ; Piazza, Roxane Maria Fontes
Fonte: Viruses. Unidade: ICB
Assuntos: MICROBIOLOGIA, ZIKA VÍRUS, PEPTÍDEOS, PROTEÍNAS RECOMBINANTES, LACTENTES, RECÉM-NASCIDO, GRAVIDEZ, INFECÇÕES POR ARBOVIRUS, INFECÇÕES POR VÍRUS DE RNA, ANTICORPOS MONOCLONAIS, ELISA, TESTES SOROLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRUDENCIO, Carlos Roberto et al. Identification of Zika Virus NS1-Derived Peptides with potential applications in serological tests. Viruses, v. 15, n. 3, p. 1-20, 2023Tradução . . Disponível em: https://doi.org/10.3390/v15030654. Acesso em: 20 jul. 2024.
APA
Prudencio, C. R., Costa, V. G. da, Rocha, L. B., Costa, H. H. M., Orts, D. J. B. y, Santos, F. R. da S., et al. (2023). Identification of Zika Virus NS1-Derived Peptides with potential applications in serological tests. Viruses, 15( 3), 1-20. doi:10.3390/v15030654
NLM
Prudencio CR, Costa VG da, Rocha LB, Costa HHM, Orts DJB y, Santos FR da S, Paula Rahal, Lino NAB, Conceição PJP da, Bittar C, Machado RRG, Durigon EL, Araujo Jr. JP, Polatto JM, Miriam Aparecida da Silva, Oliveira JA de, Mitsunari T, Pereira LR, Andreata-Santos R, Ferreira LC de S, Luz D, Piazza RMF. Identification of Zika Virus NS1-Derived Peptides with potential applications in serological tests [Internet]. Viruses. 2023 ; 15( 3): 1-20.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3390/v15030654
Vancouver
Prudencio CR, Costa VG da, Rocha LB, Costa HHM, Orts DJB y, Santos FR da S, Paula Rahal, Lino NAB, Conceição PJP da, Bittar C, Machado RRG, Durigon EL, Araujo Jr. JP, Polatto JM, Miriam Aparecida da Silva, Oliveira JA de, Mitsunari T, Pereira LR, Andreata-Santos R, Ferreira LC de S, Luz D, Piazza RMF. Identification of Zika Virus NS1-Derived Peptides with potential applications in serological tests [Internet]. Viruses. 2023 ; 15( 3): 1-20.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3390/v15030654
Artigo de periodico
Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice (2023)
Machado, R. Rahal Guaragna ; Rafael, G. H.; Scharton, D.; Campos, R. Kroon; Liang, Y.; Plante, K. S.; Weaver, S. C.; Durigon, E. L.
Fonte: International Journal of Infectious Diseases. Nome do evento: International Congress on Infectious Diseases. Unidade: ICB
Assuntos: MICROBIOLOGIA, DOENÇAS INFECCIOSAS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS, INTERFERONS, ANTICORPOS, FENÓTIPOS, CITOCINAS, LINHAGENS ANIMAIS, INFLAMAÇÃO, QUIMIOCINAS, VIROSES EM ANIMAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, R. Rahal Guaragna et al. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice. International Journal of Infectious Diseases, v. 130, p. S18, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.ijid.2023.04.044. Acesso em: 20 jul. 2024.
APA
Machado, R. R. G., Rafael, G. H., Scharton, D., Campos, R. K., Liang, Y., Plante, K. S., et al. (2023). Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice. International Journal of Infectious Diseases, 130, S18. doi:10.1016/j.ijid.2023.04.044
NLM
Machado RRG, Rafael GH, Scharton D, Campos RK, Liang Y, Plante KS, Weaver SC, Durigon EL. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice [Internet]. International Journal of Infectious Diseases. 2023 ; 130 S18.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.ijid.2023.04.044
Vancouver
Machado RRG, Rafael GH, Scharton D, Campos RK, Liang Y, Plante KS, Weaver SC, Durigon EL. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice [Internet]. International Journal of Infectious Diseases. 2023 ; 130 S18.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.ijid.2023.04.044
Artigo de periodico
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial (2022)
Sekine, Leo ; Arns, Beatriz ; Fabro, Bruna R.; Cipolatt, Murillo M.; Machado, Rafael Rahal Guaragna ; Durigon, Edison Luiz
Fonte: European Respiratory Journal. Unidade: ICB
Assuntos: MICROBIOLOGIA, PLASMA, COVID-19, ESTUDOS RANDOMIZADOS, IMUNIZAÇÃO PASSIVA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SEKINE, Leo et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal, v. 59, n. 2, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1183/13993003.02076-2021. Acesso em: 20 jul. 2024.
APA
Sekine, L., Arns, B., Fabro, B. R., Cipolatt, M. M., Machado, R. R. G., & Durigon, E. L. (2022). Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal, 59( 2), 1-11. doi:10.1183/13993003.02076-2021
NLM
Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial [Internet]. European Respiratory Journal. 2022 ; 59( 2): 1-11.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1183/13993003.02076-2021
Vancouver
Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial [Internet]. European Respiratory Journal. 2022 ; 59( 2): 1-11.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1183/13993003.02076-2021
Artigo de periodico
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) (2022)
Song, Alice Tung Wan ; Rocha, Vanderson Geraldo ; Mendrone Júnior, Alfredo ; Rodrigues, Rodrigo do Tocantins Calado de Saloma ; Santis, Gil Cunha De ; Benites, Bruno D. ; Lima, Carolina Costa ; Vargas, Taiani ; Marques, Leonardo da Silva ; Fernandes, Juliana C. ; Breda, Felipe C.; Wendel, Silvano ; Fachini, Roberta; Rizzo, Luiz V. ; Kutner, José Mauro ; Silva, Vivian Helena Iida Avelino da ; Machado, Rafael Rahal Guaragna ; Durigon, Edison Luiz ; Chevret, Sylvie ; Kallas, Esper Georges
Fonte: Lancet Regional Health. Americas. Unidades: FM, FMRP, ICB
Assuntos: MICROBIOLOGIA, COVID-19, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, PLASMA, SANGUE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SONG, Alice Tung Wan et al. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Regional Health. Americas, v. 10, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.lana.2022.100216. Acesso em: 20 jul. 2024.
APA
Song, A. T. W., Rocha, V. G., Mendrone Júnior, A., Rodrigues, R. do T. C. de S., Santis, G. C. D., Benites, B. D., et al. (2022). Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). Lancet Regional Health. Americas, 10, 1-10. doi:10.1016/j.lana.2022.100216
NLM
Song ATW, Rocha VG, Mendrone Júnior A, Rodrigues R do TC de S, Santis GCD, Benites BD, Lima CC, Vargas T, Marques L da S, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Silva VHIA da, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) [Internet]. Lancet Regional Health. Americas. 2022 ; 10 1-10.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.lana.2022.100216
Vancouver
Song ATW, Rocha VG, Mendrone Júnior A, Rodrigues R do TC de S, Santis GCD, Benites BD, Lima CC, Vargas T, Marques L da S, Fernandes JC, Breda FC, Wendel S, Fachini R, Rizzo LV, Kutner JM, Silva VHIA da, Machado RRG, Durigon EL, Chevret S, Kallas EG. Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) [Internet]. Lancet Regional Health. Americas. 2022 ; 10 1-10.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.lana.2022.100216
Artigo de periodico
Validation of serological methods for COVID-19 and retrospective screening of health employees and visitors to the São Paulo University Hospital, Brazil (2022)
Santos, Robert Andreata ; Machado, Rafael Rahal Guaragna ; Alves, Rúbens Prince dos Santos ; Sales, Natiely Silva ; Soares, Camila Pereira ; Rodrigues, Karine Bitencourt ; Andrade, Juliana Bannwart ; Fock, Ricardo Ambrósio ; Margarido, Paulo Francisco Ramos ; Carvalho, Cristiane Rodrigues Guzzo ; Boscardin, Silvia Beatriz ; Durigon, Edison Luiz ; Ferreira, Luís Carlos de Souza
Fonte: Frontiers in Cellular and Infection Microbiology. Unidades: HU, ICB, FCF, BIOTECNOLOGIA
Assuntos: MICROBIOLOGIA, PARASITOLOGIA, COVID-19, TESTES SOROLÓGICOS, TRIAGEM, SERVIÇOS DE SAÚDE, ESTUDOS RETROSPECTIVOS, ANTICORPOS, ELISA, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Robert Andreata et al. Validation of serological methods for COVID-19 and retrospective screening of health employees and visitors to the São Paulo University Hospital, Brazil. Frontiers in Cellular and Infection Microbiology, v. 12, p. 1-8, 2022Tradução . . Disponível em: https://doi.org/10.3389/fcimb.2022.787411. Acesso em: 20 jul. 2024.
APA
Santos, R. A., Machado, R. R. G., Alves, R. P. dos S., Sales, N. S., Soares, C. P., Rodrigues, K. B., et al. (2022). Validation of serological methods for COVID-19 and retrospective screening of health employees and visitors to the São Paulo University Hospital, Brazil. Frontiers in Cellular and Infection Microbiology, 12, 1-8. doi:10.3389/fcimb.2022.787411
NLM
Santos RA, Machado RRG, Alves RP dos S, Sales NS, Soares CP, Rodrigues KB, Andrade JB, Fock RA, Margarido PFR, Carvalho CRG, Boscardin SB, Durigon EL, Ferreira LC de S. Validation of serological methods for COVID-19 and retrospective screening of health employees and visitors to the São Paulo University Hospital, Brazil [Internet]. Frontiers in Cellular and Infection Microbiology. 2022 ; 12 1-8.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fcimb.2022.787411
Vancouver
Santos RA, Machado RRG, Alves RP dos S, Sales NS, Soares CP, Rodrigues KB, Andrade JB, Fock RA, Margarido PFR, Carvalho CRG, Boscardin SB, Durigon EL, Ferreira LC de S. Validation of serological methods for COVID-19 and retrospective screening of health employees and visitors to the São Paulo University Hospital, Brazil [Internet]. Frontiers in Cellular and Infection Microbiology. 2022 ; 12 1-8.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fcimb.2022.787411
Artigo de periodico
Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease (2022)
Srinivasan, Vasundara ; Brognaro, Hévila ; Prabhu, Prince R.; Souza, Edmarcia Elisa de ; Günther, Sebastian ; Reinke, Patrick Y. A.; Barra, Angélica Luana Carrilho ; Machado, Rafael Rahal Guaragna ; Durigon, Edison Luiz ; Wrenger, Carsten
Fonte: Communications Biology. Unidades: ICB, IFSC
Assuntos: MICROBIOLOGIA, PARASITOLOGIA, ANTIVIRAIS, COVID-19, ATIVAÇÃO ENZIMÁTICA, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SRINIVASAN, Vasundara et al. Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. Communications Biology, v. 5, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1038/s42003-022-03737-7. Acesso em: 20 jul. 2024.
APA
Srinivasan, V., Brognaro, H., Prabhu, P. R., Souza, E. E. de, Günther, S., Reinke, P. Y. A., et al. (2022). Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. Communications Biology, 5, 1-12. doi:10.1038/s42003-022-03737-7
NLM
Srinivasan V, Brognaro H, Prabhu PR, Souza EE de, Günther S, Reinke PYA, Barra ALC, Machado RRG, Durigon EL, Wrenger C. Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease [Internet]. Communications Biology. 2022 ; 5 1-12.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1038/s42003-022-03737-7
Vancouver
Srinivasan V, Brognaro H, Prabhu PR, Souza EE de, Günther S, Reinke PYA, Barra ALC, Machado RRG, Durigon EL, Wrenger C. Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease [Internet]. Communications Biology. 2022 ; 5 1-12.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1038/s42003-022-03737-7
Artigo de periodico
Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape (2021)
Santos, Keity Souza ; Oliveira, Jamille Ramos de ; Machado, Rafael Rahal Guaragna ; Arcuri, Helen Andrade; Magawa, Jhosiene Yukari; Daher, Isabela Pazotti; Urbanski, Alysson Henrique; Schmitz, Gabriela Justamante Handel; Silva Júnior, Roberto Carlos Vieira; Durigon, Edison Luiz ; Boscardin, Silvia Beatriz ; Rosa, Daniela Santoro ; Schechtman, Deborah ; Cunha Neto, Edecio ; Gadermaier, Gabriele; Coelho, Verônica Porto Carreiro de Vasconcellos; Kalil, Jorge; Nakaya, Helder Takashi Imoto
Fonte: medRxiv (The Preprint Server For Health Sciences). Unidades: FM, ICB, IQ, FCF
Assuntos: EPITOPOS, COVID-19, ANTICORPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Keity Souza et al. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape. medRxiv (The Preprint Server For Health Sciences), p. 18 , 2021Tradução . . Disponível em: https://doi.org/10.1101/2021.03.11.21253399. Acesso em: 20 jul. 2024.
APA
Santos, K. S., Oliveira, J. R. de, Machado, R. R. G., Arcuri, H. A., Magawa, J. Y., Daher, I. P., et al. (2021). Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape. medRxiv (The Preprint Server For Health Sciences), 18 . doi:10.1101/2021.03.11.21253399
NLM
Santos KS, Oliveira JR de, Machado RRG, Arcuri HA, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Silva Júnior RCV, Durigon EL, Boscardin SB, Rosa DS, Schechtman D, Cunha Neto E, Gadermaier G, Coelho VPC de V, Kalil J, Nakaya HTI. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape [Internet]. medRxiv (The Preprint Server For Health Sciences). 2021 ; 18 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1101/2021.03.11.21253399
Vancouver
Santos KS, Oliveira JR de, Machado RRG, Arcuri HA, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Silva Júnior RCV, Durigon EL, Boscardin SB, Rosa DS, Schechtman D, Cunha Neto E, Gadermaier G, Coelho VPC de V, Kalil J, Nakaya HTI. Immunodominant B cell epitope in SARS-CoV-2 RBD comprises a B.1.351 and P.1 mutation hotspot: implications for viral spread and antibody escape [Internet]. medRxiv (The Preprint Server For Health Sciences). 2021 ; 18 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1101/2021.03.11.21253399
Artigo de periodico
Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial (2021)
Bertanha, Matheus ; Rodrigues, Lenize da Silva ; Mellucci Filho, Pedro Luciano ; Moroz, Andrei ; Pardini, Maria Inês de Moura Campos ; Sobreira, Marcone Lima ; Durigon, Edison Luiz ; Machado, Rafael Rahal Guaragna ; Carvalho, Cristiane Rodrigues Guzzo
Fonte: Medicine. Unidade: ICB
Assuntos: MICROBIOLOGIA, ANTICOAGULANTES, POLISSACARÍDEOS, CORONAVIRUS, DOENÇAS RESPIRATÓRIAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, COVID-19, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERTANHA, Matheus et al. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial. Medicine, v. 100, n. 51, p. 1-7, 2021Tradução . . Disponível em: https://doi.org/10.1097/MD.0000000000028288. Acesso em: 20 jul. 2024.
APA
Bertanha, M., Rodrigues, L. da S., Mellucci Filho, P. L., Moroz, A., Pardini, M. I. de M. C., Sobreira, M. L., et al. (2021). Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial. Medicine, 100( 51), 1-7. doi:10.1097/MD.0000000000028288
NLM
Bertanha M, Rodrigues L da S, Mellucci Filho PL, Moroz A, Pardini MI de MC, Sobreira ML, Durigon EL, Machado RRG, Carvalho CRG. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial [Internet]. Medicine. 2021 ; 100( 51): 1-7.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1097/MD.0000000000028288
Vancouver
Bertanha M, Rodrigues L da S, Mellucci Filho PL, Moroz A, Pardini MI de MC, Sobreira ML, Durigon EL, Machado RRG, Carvalho CRG. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial [Internet]. Medicine. 2021 ; 100( 51): 1-7.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1097/MD.0000000000028288
Artigo de periodico
Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells (2021)
Machado, Rafael Rahal Guaragna ; Glaser, Talita ; Araujo, Danielle Bastos ; Petiz, Lyvia Lintzmaier ; Durigon, Danielle Bruna Leal de Oliveira ; Durigon, Giuliana Stravinskas; Leal, Alessandra L.; Pinho, Joao Renato Rebello ; Ferreira, Luís Carlos de Souza ; Ulrich, Henning ; Durigon, Edison Luiz ; Carvalho, Cristiane Rodrigues Guzzo
Fonte: ACS Pharmacolology and Translational Science. Unidades: ICB, FM, IQ
Assuntos: COVID-19, REPLICAÇÃO VIRAL, SAIS, MICROBIOLOGIA, CÉLULAS EPITELIAIS, CORONAVIRUS, SÍNDROME CORONARIANA AGUDA, DOENÇAS RESPIRATÓRIAS, MEMBRANA PLASMÁTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO, Rafael Rahal Guaragna et al. Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells. ACS Pharmacolology and Translational Science, v. 4, n. 5, p. 1514–1527, 2021Tradução . . Disponível em: https://doi.org/10.1021/acsptsci.1c00080. Acesso em: 20 jul. 2024.
APA
Machado, R. R. G., Glaser, T., Araujo, D. B., Petiz, L. L., Durigon, D. B. L. de O., Durigon, G. S., et al. (2021). Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells. ACS Pharmacolology and Translational Science, 4( 5), 1514–1527. doi:10.1021/acsptsci.1c00080
NLM
Machado RRG, Glaser T, Araujo DB, Petiz LL, Durigon DBL de O, Durigon GS, Leal AL, Pinho JRR, Ferreira LC de S, Ulrich H, Durigon EL, Carvalho CRG. Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells [Internet]. ACS Pharmacolology and Translational Science. 2021 ; 4( 5): 1514–1527.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1021/acsptsci.1c00080
Vancouver
Machado RRG, Glaser T, Araujo DB, Petiz LL, Durigon DBL de O, Durigon GS, Leal AL, Pinho JRR, Ferreira LC de S, Ulrich H, Durigon EL, Carvalho CRG. Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells [Internet]. ACS Pharmacolology and Translational Science. 2021 ; 4( 5): 1514–1527.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1021/acsptsci.1c00080
Artigo de periodico
Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial (2021)
Santos, Paulo Sérgio da Silva ; Orcina, Bernardo da Fonseca ; Machado, Rafael Rahal Guaragna ; Vilhena, Fabiano Vieira ; Alves, Lucas Marques da Costa ; Zangrando, Mariana Schutzer Ragghianti ; Oliveira, Rodrigo Cardoso de ; Soares, Mariana Quirino Silveira ; Simão, Andréa Name Colado ; Pietro, Emilene Cristine Izu Nakamura ; Kuroda, Juliana Pescinelli Garcia ; Benjamim, Ivanilda Aparecida de Almeida; Araujo, Danielle Bastos ; Toma, Sérgio Hiroshi ; Flor, Lourival; Araki, Koiti ; Durigon, Edison Luiz
Fonte: Scientific Reports. Unidades: FOB, IQ, ICB
Assuntos: ANTISSÉPTICOS BUCAIS, COVID-19, ANTIVIRAIS, EPIDEMIOLOGIA, MICROBIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Paulo Sérgio da Silva et al. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial. Scientific Reports, v. 11, p. 1-10, 2021Tradução . . Disponível em: https://doi.org/10.1038/s41598-021-99013-5. Acesso em: 20 jul. 2024.
APA
Santos, P. S. da S., Orcina, B. da F., Machado, R. R. G., Vilhena, F. V., Alves, L. M. da C., Zangrando, M. S. R., et al. (2021). Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial. Scientific Reports, 11, 1-10. doi:10.1038/s41598-021-99013-5
NLM
Santos PS da S, Orcina B da F, Machado RRG, Vilhena FV, Alves LM da C, Zangrando MSR, Oliveira RC de, Soares MQS, Simão ANC, Pietro ECIN, Kuroda JPG, Benjamim IA de A, Araujo DB, Toma SH, Flor L, Araki K, Durigon EL. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial [Internet]. Scientific Reports. 2021 ; 11 1-10.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1038/s41598-021-99013-5
Vancouver
Santos PS da S, Orcina B da F, Machado RRG, Vilhena FV, Alves LM da C, Zangrando MSR, Oliveira RC de, Soares MQS, Simão ANC, Pietro ECIN, Kuroda JPG, Benjamim IA de A, Araujo DB, Toma SH, Flor L, Araki K, Durigon EL. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial [Internet]. Scientific Reports. 2021 ; 11 1-10.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1038/s41598-021-99013-5
Artigo de periodico
Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing (2021)
Mendrone Junior, Alfredo ; Dinardo, Carla Luana ; Ferreira, Suzete Cleuza ; Nishya, Anna ; Salles, Nanci Alves; Almeida Neto, Cesar de ; Hamasaki, Debora Toshei; Facincani, Tila ; Alves, Lucas Bassolli de Oliveira ; Machado, Rafael Rahal Guaragna ; Araujo, Danielle Bastos ; Durigon, Edison Luiz ; Rocha, Vanderson Geraldo ; Sabino, Ester Cerdeira
Fonte: Transfusion. Unidades: ICB, FM
Assuntos: MICROBIOLOGIA, COVID-19, IMUNOENSAIO, IMUNOGLOBULINAS, ANTICORPOS, TESTES IMUNOLÓGICOS, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MENDRONE JUNIOR, Alfredo et al. Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion, p. 10 , 2021Tradução . . Disponível em: https://doi.org/10.1111/trf.16268. Acesso em: 20 jul. 2024.
APA
Mendrone Junior, A., Dinardo, C. L., Ferreira, S. C., Nishya, A., Salles, N. A., Almeida Neto, C. de, et al. (2021). Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing. Transfusion, 10 . doi:10.1111/trf.16268
NLM
Mendrone Junior A, Dinardo CL, Ferreira SC, Nishya A, Salles NA, Almeida Neto C de, Hamasaki DT, Facincani T, Alves LB de O, Machado RRG, Araujo DB, Durigon EL, Rocha VG, Sabino EC. Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing [Internet]. Transfusion. 2021 ;10 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16268
Vancouver
Mendrone Junior A, Dinardo CL, Ferreira SC, Nishya A, Salles NA, Almeida Neto C de, Hamasaki DT, Facincani T, Alves LB de O, Machado RRG, Araujo DB, Durigon EL, Rocha VG, Sabino EC. Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing [Internet]. Transfusion. 2021 ;10 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16268
Artigo de periodico
Anti‐A and SARS‐CoV‐2: an intriguing association (2021)
Dutra, Valeria de Freitas ; Bub, Carolina Bonet ; Yokoyama, Ana Paula Hitomi ; Achkar, Ruth; Machado, Rafael Rahal Guaragna ; Assunção, Murilo; Candelelaria, Gabriela; Soares, Camila Pereira ; Fachini, Roberta Maria; Wendel, Rita Fontão; Hamerschlak, Nelson ; Reis, Luiz Fernando Lima; Araujo, Danielle Bastos ; Nudelman, Victor ; Pinho, João R. R. ; Rizzo, Luiz Vicente ; Sakashita, Araci M. ; Scuracchio, Patrícia; Durigon, Edison Luiz ; Wendel, Silvano ; Kutner, José Mauro
Fonte: Vox Sanguinis. Unidade: ICB
Assuntos: MICROBIOLOGIA, COVID-19, GRUPOS SANGUÍNEOS, INFECÇÕES POR CORONAVIRUS, PLASMA, REAÇÃO EM CADEIA POR POLIMERASE, IMUNOGLOBULINAS, ESTUDOS DE COORTES, ESTUDOS RETROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DUTRA, Valeria de Freitas et al. Anti‐A and SARS‐CoV‐2: an intriguing association. Vox Sanguinis, p. 7 , 2021Tradução . . Disponível em: https://doi.org/10.1111/vox.13044. Acesso em: 20 jul. 2024.
APA
Dutra, V. de F., Bub, C. B., Yokoyama, A. P. H., Achkar, R., Machado, R. R. G., Assunção, M., et al. (2021). Anti‐A and SARS‐CoV‐2: an intriguing association. Vox Sanguinis, 7 . doi:10.1111/vox.13044
NLM
Dutra V de F, Bub CB, Yokoyama APH, Achkar R, Machado RRG, Assunção M, Candelelaria G, Soares CP, Fachini RM, Wendel RF, Hamerschlak N, Reis LFL, Araujo DB, Nudelman V, Pinho JRR, Rizzo LV, Sakashita AM, Scuracchio P, Durigon EL, Wendel S, Kutner JM. Anti‐A and SARS‐CoV‐2: an intriguing association [Internet]. Vox Sanguinis. 2021 ;7 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/vox.13044
Vancouver
Dutra V de F, Bub CB, Yokoyama APH, Achkar R, Machado RRG, Assunção M, Candelelaria G, Soares CP, Fachini RM, Wendel RF, Hamerschlak N, Reis LFL, Araujo DB, Nudelman V, Pinho JRR, Rizzo LV, Sakashita AM, Scuracchio P, Durigon EL, Wendel S, Kutner JM. Anti‐A and SARS‐CoV‐2: an intriguing association [Internet]. Vox Sanguinis. 2021 ;7 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/vox.13044
Artigo de periodico
Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies (2021)
Carvalho, Aléxia Adrianne Venceslau ; Favaro, Marianna Teixeira de Pinho ; Pereira, Lennon Ramos ; Jesus, Mônica Josiane Rodrigues ; Pereira, Samuel Santos ; Santos, Robert Andreata ; Alves, Rúbens Prince dos Santos ; Amarante, Maria Fernanda Castro ; Rodrigues, Karine Bitencourt ; Silva, Jamile Ramos da ; Machado, Rafael Rahal Guaragna ; Cunha, Marielton dos Passos ; Zanotto, Paolo Marinho de Andrade ; Fotoran, Wesley Luzetti ; Wunderlich, Gerhard ; Durigon, Edison Luiz ; Ferreira, Luís Carlos de Souza
Fonte: Nanomedicine: Nanotechnology, Biology and Medicine. Unidades: ICB, BIOTECNOLOGIA
Assuntos: PARASITOLOGIA, MICROBIOLOGIA, VÍRUS CHIKUNGUNYA, PROTEÍNAS RECOMBINANTES, VÍRUS DE RNA, NANOPARTÍCULAS, ANTICORPOS, INFLAMAÇÃO, VACINAS VIRAIS, ADJUVANTES IMUNOLÓGICOS, CAMUNDONGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARVALHO, Aléxia Adrianne Venceslau et al. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies. Nanomedicine: Nanotechnology, Biology and Medicine, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.nano.2021.102445. Acesso em: 20 jul. 2024.
APA
Carvalho, A. A. V., Favaro, M. T. de P., Pereira, L. R., Jesus, M. J. R., Pereira, S. S., Santos, R. A., et al. (2021). Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies. Nanomedicine: Nanotechnology, Biology and Medicine. doi:10.1016/j.nano.2021.102445
NLM
Carvalho AAV, Favaro MT de P, Pereira LR, Jesus MJR, Pereira SS, Santos RA, Alves RP dos S, Amarante MFC, Rodrigues KB, Silva JR da, Machado RRG, Cunha M dos P, Zanotto PM de A, Fotoran WL, Wunderlich G, Durigon EL, Ferreira LC de S. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies [Internet]. Nanomedicine: Nanotechnology, Biology and Medicine. 2021 ;[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.nano.2021.102445
Vancouver
Carvalho AAV, Favaro MT de P, Pereira LR, Jesus MJR, Pereira SS, Santos RA, Alves RP dos S, Amarante MFC, Rodrigues KB, Silva JR da, Machado RRG, Cunha M dos P, Zanotto PM de A, Fotoran WL, Wunderlich G, Durigon EL, Ferreira LC de S. Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies [Internet]. Nanomedicine: Nanotechnology, Biology and Medicine. 2021 ;[citado 2024 jul. 20 ] Available from: https://doi.org/10.1016/j.nano.2021.102445
Artigo de periodico
Neonatal consequences of maternal exposure to the chikungunya virus (2021)
Fajardo, Thamirys Cosmo Grillo ; Gazeta, Rosa Estela ; Catalan, Daniel Thome; Mello, Alexandra Siqueira; Silva, Andrea Cristina Botelho da; Bertozzi, Ana Paula Antunes Pascalicchio ; Santos, Geovane Ribeiro Dos ; Pinto, Clóvis Antonio Lopes; Oliveira, Cairo Monteiro de ; Machado, Rafael Rahal Guaragna ; Durigon, Danielle Bruna Leal de Oliveira ; Durigon, Edison Luiz ; Passos, Saulo Duarte
Fonte: Medicine. Unidade: ICB
Assuntos: MICROBIOLOGIA, VÍRUS CHIKUNGUNYA, INFECÇÕES POR VÍRUS DE RNA, GRAVIDEZ, TRANSTORNOS MOTORES, TRANSTORNOS NEUROPSICOLÓGICOS, TESTES SOROLÓGICOS, RECÉM-NASCIDO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FAJARDO, Thamirys Cosmo Grillo et al. Neonatal consequences of maternal exposure to the chikungunya virus. Medicine, v. 100, n. 17, p. 1-5, 2021Tradução . . Disponível em: https://doi.org/10.1097/MD.0000000000025695. Acesso em: 20 jul. 2024.
APA
Fajardo, T. C. G., Gazeta, R. E., Catalan, D. T., Mello, A. S., Silva, A. C. B. da, Bertozzi, A. P. A. P., et al. (2021). Neonatal consequences of maternal exposure to the chikungunya virus. Medicine, 100( 17), 1-5. doi:10.1097/MD.0000000000025695
NLM
Fajardo TCG, Gazeta RE, Catalan DT, Mello AS, Silva ACB da, Bertozzi APAP, Santos GRD, Pinto CAL, Oliveira CM de, Machado RRG, Durigon DBL de O, Durigon EL, Passos SD. Neonatal consequences of maternal exposure to the chikungunya virus [Internet]. Medicine. 2021 ; 100( 17): 1-5.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1097/MD.0000000000025695
Vancouver
Fajardo TCG, Gazeta RE, Catalan DT, Mello AS, Silva ACB da, Bertozzi APAP, Santos GRD, Pinto CAL, Oliveira CM de, Machado RRG, Durigon DBL de O, Durigon EL, Passos SD. Neonatal consequences of maternal exposure to the chikungunya virus [Internet]. Medicine. 2021 ; 100( 17): 1-5.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1097/MD.0000000000025695
Artigo de periodico
Case Report: A severe SARS-CoV-2 infection in a teenager with Angelman Syndrome (2021)
Lopes, Alessandra G. D. ; Celestino, Camila S. H. ; Barros, Tiago T. A.; Fevereiro, Aline G. ; Gejer, Debora H.; Oliveira, Fernando M. F.; Brasil, Jamile M. ; Bossolan, Rosely M.; Pinto, Gabriela C. C.; Santos, Ana C. E. Z.; Divan, Luis A.; Alves, Ingrid A. B.; Oliveira, Danielle Bruno Leal ; Machado, Rafael Rahal Guaragna ; Thomazelli, Luciano Matsumiya ; Hiyane, Meire Ioshie ; Abreu, Leonília Brelaz ; Jardim, Elayne Bragança ; Heinen, Letícia B. S. ; Barrientos, Anna C. M. ; Mau, Luciana Becker ; Câmara, Niels Olsen Saraiva ; Bueno, Daniela Franco ; Amano, Mariane Tami
Fonte: Frontiers in Medicine. Unidade: ICB
Assuntos: IMUNOLOGIA, COVID-19, INFLAMAÇÃO, ANTICORPOS, SÍNDROME DE ANGELMAN, ADOLESCENTES, INFECÇÕES RESPIRATÓRIAS, INFECÇÕES POR VÍRUS DE RNA, CORONAVIRUS, VÍRUS DE RNA, INFECÇÕES POR CORONAVIRUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Alessandra G. D. et al. Case Report: A severe SARS-CoV-2 infection in a teenager with Angelman Syndrome. Frontiers in Medicine, v. 8, p. 1-8, 2021Tradução . . Disponível em: https://doi.org/10.3389/fmed.2021.629112. Acesso em: 20 jul. 2024.
APA
Lopes, A. G. D., Celestino, C. S. H., Barros, T. T. A., Fevereiro, A. G., Gejer, D. H., Oliveira, F. M. F., et al. (2021). Case Report: A severe SARS-CoV-2 infection in a teenager with Angelman Syndrome. Frontiers in Medicine, 8, 1-8. doi:10.3389/fmed.2021.629112
NLM
Lopes AGD, Celestino CSH, Barros TTA, Fevereiro AG, Gejer DH, Oliveira FMF, Brasil JM, Bossolan RM, Pinto GCC, Santos ACEZ, Divan LA, Alves IAB, Oliveira DBL, Machado RRG, Thomazelli LM, Hiyane MI, Abreu LB, Jardim EB, Heinen LBS, Barrientos ACM, Mau LB, Câmara NOS, Bueno DF, Amano MT. Case Report: A severe SARS-CoV-2 infection in a teenager with Angelman Syndrome [Internet]. Frontiers in Medicine. 2021 ; 8 1-8.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fmed.2021.629112
Vancouver
Lopes AGD, Celestino CSH, Barros TTA, Fevereiro AG, Gejer DH, Oliveira FMF, Brasil JM, Bossolan RM, Pinto GCC, Santos ACEZ, Divan LA, Alves IAB, Oliveira DBL, Machado RRG, Thomazelli LM, Hiyane MI, Abreu LB, Jardim EB, Heinen LBS, Barrientos ACM, Mau LB, Câmara NOS, Bueno DF, Amano MT. Case Report: A severe SARS-CoV-2 infection in a teenager with Angelman Syndrome [Internet]. Frontiers in Medicine. 2021 ; 8 1-8.[citado 2024 jul. 20 ] Available from: https://doi.org/10.3389/fmed.2021.629112
Artigo de periodico
Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be? (2021)
Wendel, Silvano ; Fachini, Roberta ; Wendel, Rita C. L. Fontão; Santos, Ralyria Mello Vieira dos ; Velasquez, Carlos Vinícius; Machado, Rafael Rahal Guaragna ; Brito, Mayra Altobelli; Amaral, Marcelo; Soares, Camila Pereira ; Achkar, Ruth; Scuracchio, Patrícia ; Miyaji, Sandra Cristina; Erdens, Melina Santos; Durigon, Edison Luiz
Fonte: Transfusion. Unidade: ICB
Assuntos: MICROBIOLOGIA, ANTIVIRAIS, COVID-19, DOADORES DE SANGUE, TESTES SOROLÓGICOS, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WENDEL, Silvano et al. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?. Transfusion, v. 61, n. 12, p. 3455-3467, 2021Tradução . . Disponível em: https://doi.org/10.1111/trf.16714. Acesso em: 20 jul. 2024.
APA
Wendel, S., Fachini, R., Wendel, R. C. L. F., Santos, R. M. V. dos, Velasquez, C. V., Machado, R. R. G., et al. (2021). Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be? Transfusion, 61( 12), 3455-3467. doi:10.1111/trf.16714
NLM
Wendel S, Fachini R, Wendel RCLF, Santos RMV dos, Velasquez CV, Machado RRG, Brito MA, Amaral M, Soares CP, Achkar R, Scuracchio P, Miyaji SC, Erdens MS, Durigon EL. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be? [Internet]. Transfusion. 2021 ; 61( 12): 3455-3467.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16714
Vancouver
Wendel S, Fachini R, Wendel RCLF, Santos RMV dos, Velasquez CV, Machado RRG, Brito MA, Amaral M, Soares CP, Achkar R, Scuracchio P, Miyaji SC, Erdens MS, Durigon EL. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be? [Internet]. Transfusion. 2021 ; 61( 12): 3455-3467.[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16714
Artigo de periodico
A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections (2021)
Wendel, Silvano ; Wendel, Rita Fontão; Fachini, Roberta; Candelaria, Gabriela ; Scuracchio, Patricia; Achkar, Ruth; Brito, Mayra; Reis, Luiz Fernando ; Camargo, Anamaria ; Amano, Mariane ; Machado, Rafael Rahal Guaragna ; Araujo, Danielle Bastos ; Soares, Camila Pereira ; Durigon, Edison Luiz
Fonte: Transfusion. Unidade: ICB
Assuntos: MICROBIOLOGIA, SANGUE, PLASMA, COVID-19, ESTUDOS LONGITUDINAIS, CINÉTICA QUÍMICA, ANTICORPOS, REAÇÃO EM CADEIA POR POLIMERASE, ESTUDOS DE COORTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WENDEL, Silvano et al. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections. Transfusion, p. 14 , 2021Tradução . . Disponível em: https://doi.org/10.1111/trf.16323. Acesso em: 20 jul. 2024.
APA
Wendel, S., Wendel, R. F., Fachini, R., Candelaria, G., Scuracchio, P., Achkar, R., et al. (2021). A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections. Transfusion, 14 . doi:10.1111/trf.16323
NLM
Wendel S, Wendel RF, Fachini R, Candelaria G, Scuracchio P, Achkar R, Brito M, Reis LF, Camargo A, Amano M, Machado RRG, Araujo DB, Soares CP, Durigon EL. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections [Internet]. Transfusion. 2021 ;14 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16323
Vancouver
Wendel S, Wendel RF, Fachini R, Candelaria G, Scuracchio P, Achkar R, Brito M, Reis LF, Camargo A, Amano M, Machado RRG, Araujo DB, Soares CP, Durigon EL. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections [Internet]. Transfusion. 2021 ;14 .[citado 2024 jul. 20 ] Available from: https://doi.org/10.1111/trf.16323

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Editora

Grupo de pesquisa

Agência de fomento

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos